A Phase IIa Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination with Paclitaxel versus Paclitaxel alone in Patients with Metastatic, Gastric or Gastro-oesophageal Junction, Cancer who progress following First Line Therapy and are Ineligible for Treatment with trastuzumab by HER2 Status (SAGE)

Trial Profile

A Phase IIa Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination with Paclitaxel versus Paclitaxel alone in Patients with Metastatic, Gastric or Gastro-oesophageal Junction, Cancer who progress following First Line Therapy and are Ineligible for Treatment with trastuzumab by HER2 Status (SAGE)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2017

At a glance

  • Drugs Sapitinib (Primary) ; Paclitaxel
  • Indications Gastric cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms SAGE
  • Most Recent Events

    • 08 Nov 2012 Status changed from recruiting to discontinued, according to the European Clinical Trials Database record.
    • 22 Jun 2012 Planned End Date changed from 1 May 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
    • 22 May 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top